The clinical value of Thinprep cytology test combined with h -TERC and c -myc in the diagnosis of cervical ;cancer / 中国基层医药

ABSTRACT

Objective To explore the clinical value of Thinprep cytology test (TCT)combined with h -TERC and c -myc in the diagnosis of cervical cancer.Methods hTERC amplification was detected by dual -color interphase fluorescence in situ hybridization (FISH),and the results were compared with TCT and histological examination.Examination the positive which TCT,h -TERC and c -myc by pathological examination.The final diag-nosis was determined by the pathological examination.Results TCT was abnormal in 26.4% of 500 case,18.0%abnormal h -TERC gene,16.0% abnormal c -myc gene.In 270 cases according to the cervical biopsy,the positive rate of chronic inflammation,cervical intraepithelial neoplasia (CIN)Ⅰ,CINⅡ,CINⅢ and cervical cancer:44.4%, 38.2%,36.4%,18.2%,and 7.3% respectively.The positive rates of h -TERC were 18.1%,45.4%,52.5%, 65.9% and 100.0%,respectively.The positive rates of c -myc were 21.4%,48.9%,56.7%,59.9% and 100.0%.With increased pathological grade,the expressions of h -TERC and c -myc were high.Conclusion TCT combined with h -TERC and c -myc can test cervical cancer more effective.